Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
21.66
+1.66 (8.30%)
Jan 21, 2025, 4:00 PM EST - Market closed
Dianthus Therapeutics Employees
Dianthus Therapeutics had 53 employees as of December 31, 2023. The number of employees increased by 21 or 65.63% compared to the previous year.
Employees
53
Change (1Y)
21
Growth (1Y)
65.63%
Revenue / Employee
$101,245
Profits / Employee
-$1,265,887
Market Cap
641.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
DNTH News
- 13 days ago - Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - GlobeNewsWire
- 5 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
- 6 months ago - Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition - Seeking Alpha
- 7 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) - GlobeNewsWire
- 7 months ago - Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) - GlobeNewsWire